Ask AI
Beyond A1C in T2D TM 3

CE / CME

Looking Beyond A1C in T2D Care: Evidence Integration and Clinical Positioning

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: August 07, 2026

Expiration: August 06, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Jay H. Shubrook, DO, FAAFP, FACOFP, discusses strategies healthcare professionals (HCPs) can take to move type 2 diabetes (T2D) care beyond A1C alone, with a focus on integrating cardiovascular–kidney–metabolic (CKM) risk assessment and novel organ-protective therapies in individualized care plans. Through guideline-based recommendations and an interactive patient case, learners will explore the latest evidence for implementing incretin-based therapies and other organ-protective agents in modern T2D treatment plans for patients with relevant CKM comorbidities being seen in the primary care setting.

The key points discussed in this module are illustrated with thumbnails that can be enlarged by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with diabetes do you provide care for in a typical week?​

For those who practice in academic or community settings, please indicate your practice setting:

A 58-year-old patient with T2D started a weekly GLP-1–based therapy 3 weeks ago. They report nausea, early satiety, and constipation. They have not had severe abdominal pain, vomiting, dehydration, or gallbladder symptoms. They are considering stopping therapy. 

Which strategy best supports long-term persistence and adherence?